Contact
Please use this form to send email to PR contact of this press release:
联拓生物宣布SHP2抑制剂BBP-398联合奥希替尼治疗EGFR突变阳性非小细胞肺癌患者的I期临床试验已完成首例患者给药
TO:
Please use this form to send email to PR contact of this press release:
联拓生物宣布SHP2抑制剂BBP-398联合奥希替尼治疗EGFR突变阳性非小细胞肺癌患者的I期临床试验已完成首例患者给药
TO: